# Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC

> **NCT02774187** · PHASE3 · COMPLETED · sponsor: **Sun Yat-sen University** · enrollment: 247 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Sorafenib
- **PROCEDURE:** Hepatic arterial infusion chemotherapy
- **DRUG:** Folfox Protocol

## Key facts

- **NCT ID:** NCT02774187
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-05
- **Primary completion:** 2017-07
- **Final completion:** 2018-08
- **Target enrollment:** 247 (ACTUAL)
- **Last updated:** 2019-12-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02774187

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02774187, "Sorafenib Alone Versus Sorafenib Combined With HAIC for Advanced HCC". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02774187. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*